Viewing Study NCT03055858


Ignite Creation Date: 2025-12-25 @ 12:10 AM
Ignite Modification Date: 2026-03-22 @ 4:42 PM
Study NCT ID: NCT03055858
Status: COMPLETED
Last Update Posted: 2025-02-11
First Post: 2017-02-14
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: AMPLATZER Duct Occluder II Additional Sizes
Sponsor: Abbott Medical Devices
Organization:

Study Overview

Official Title: AMPLATZER Duct Occluder II Additional Sizes Clinical Study
Status: COMPLETED
Status Verified Date: 2025-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ADO II AS
Brief Summary: The ADO II AS Study is a single arm, prospective, multicenter, nonrandomized clinical investigation to characterize the safety and effectiveness of the ADO II AS device in patients with a patent ductus arteriosus (PDA). Subjects will be implanted with the ADO II AS device using a transcatheter femoral vessel approach under fluoroscopic and echocardiographic guidance.

To account for subject dropout, up to 50 subjects will be enrolled in this clinical investigation. Up to an additional 150 subjects may be enrolled under continued access. The clinical investigation will be conducted at up to 10 centers in the United States.

Subjects participating in this clinical investigation will be followed for 3 years. The expected duration of enrollment is 18 months. The total duration of the clinical investigation is expected to be 4.5 years.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: True
Is an Unapproved Device?: True
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: